We’re reaching goals by creating innovative options to reduce LDL-cholesterol. Today, we have two treatments, approved in the U.S. and Europe, based on a unique mechanism of action that represent an important step forward. By partnering with strong commercial organizations, such as Daiichi-Sankyo, we’re working to enable broad access to our medicines globally.


We’re reaching goals by harnessing innovative science in order to explore new therapies that address both cardiovascular and cardiometabolic risk. As we look to the future, we’re working to build a pipeline of treatments that are not only focused on lowering  cholesterol.

Working Here

We’re reaching goals by attracting the best and brightest minds in the industry to work on the forefront of cardiovascular care. If you are interested in joining the Esperion team of innovative colleagues who are passionately committed to making a difference in patients’ lives.